Ask a Question

You visited our site and still have questions? Feel free to contact us

Consultation and guidance given not in the framework of service does not serve as a replacement for a physician’s examination or consultation, and is not considered a “medical diagnosis” or “medical opinion". In all cases of urgency, distress or emergency (physical and/or mental), seek medical care with a family doctor, closest emergency room, and/or ambulatory service.   

Start service

Share

Terms of use

Medix FTP Service (the "Service") is designed to provide you with an easy way to transfer files relevant to the management of your case to Medix Medical Services Europe Limited ("Medix", "we" and "us").

 

The following terms and conditions together with the Medix Information Security Policy (which may be found at http://medix- europe.com/Information_Security_Policy.aspx) (together, the "Terms of Service"), form the agreement between you and us in relation to your use of the Service. You should read the Terms of Service carefully before agreeing to them. If you do not understand any part of the Terms of Services, then please contact us at axa-ppp-intl@medix-europe.com for further information. You acknowledge and agree that by clicking on the "Upload" button, you are indicating that you accept the Terms of Services and agree to be bound by them.

 

Using the Service

 

In order to use the Service, you will be required to log in by submitting your member number which was provided to you by the Medix staff, your name and e-mail address. Once you have logged in, you will be able to upload files to the Service. We will download your files to our system and no copy will be retained on the server used to provide the Service. For detailed upload instructions, please click here.

 

Protection of your information

 

We take the safeguarding of your information very seriously. In order to prevent unauthorised access or disclosure of your information we have put in place appropriate physical, electronic and administrative procedures to safeguard and secure the files you upload to the Service. However, no method of transmission over the internet, or method of electronic data storage is 100% secure and while we have put in place appropriate protections, we cannot guarantee the security of information you upload to the Service.

 

Quality and availability of the Service

 

While we make reasonable efforts to provide the Service, it is provided "as is" with no representation, guarantee or warranty of any kind as to its availability, functionality, that it will meet your requirements or that it will be free of errors or viruses.

 

We will not be responsible for any damage to your computer system or the computer system of any third party resulting from your use of the Services where such damage is caused by circumstances which are beyond our reasonable control.

 

I agree
close
Start service
Start service
HomeMedical Information CancerTwo for the price of one: Incredible results with the latest immunotherapy treatment

Two for the price of one: Incredible results with the latest immunotherapy treatment

8/23/2017 | By: Medix Team

82% of the leukemia patients and 59% of lymphoma patients treated in a CTL019 phase II trial achieved remission.

The term immunotherapy is often thrown around regarding the cutting edge of cancer therapies. So what is it? Simply put, immunotherapy treatments help the immune system fight off cancer more effectively than it would on its own. Immune systems fight cancer just as they would fight the flu or a cold, the problem is that it often has trouble identifying and targeting the cancer cells. Immunotherapy solves this problem, strengthening the immune system and directing it against cancerous cells. Treatments are available for specific kinds of cancer, and research is currently investigating the use of this method for additional kinds.

 

The latest buzz in this field of medicine is around a drug named CTL019. Over the past months, the FDA advisory committee unanimously voted to recommend approval of the drug as second line treatment of pediatric and young adult leukemia. Meaning the drug would be available to patients which the regular treatments no longer help. This recommendation follows after the drug received “Breakthrough Therapy Designation”. This means that evidence from the clinical trials were extremely promising and authorizing the drug for widespread use can be done more quickly than other experimental drugs. This designation was granted after 82% of the patients treated in a phase II trial achieved remission. These results are outstanding and rarely seen in cancer treatment trials. For comparison, previous studies investigating treatment for patients with relapsed cancer, meaning cancer that returned after initial treatment, stood at 18%. 

 

More recently, the same therapy has received another breakthrough designation, this time for treatment of adults with lymphoma whose disease hasn’t responded to any other available treatment. Here too, the trials results were unprecedented; the drug was effective in reducing tumor size and achieving remission in 59% of treated patients. This figure is all the more impressive seeing as these patients haven’t responded to other treatments and lack any alternatives.   

 

The approval process for this drug is under way and it may take a while longer, however for patients suffering from lymphoma, the future can seem a little brighter. 

By continuing to use this site you consent to the use of cookies on your device as described in our cookie policy unless you have disabled them. You can change your cookie settings at any time but parts of our site will not function correctly without them.

ok